Welcome to Roche Foundation Medicine.

This site is not intended to provide medical advice and/or treatment guidance. It is produced by Roche as a partner of Foundation Medicine.

Please select an option:

Orange

 

 

 

Our service for diagnostic, prognostic and predictive insights to support treatment of haematological malignancies and sarcomas.1

Order FoundationOne Heme - insights for the treatment of haematological malignancies and sarcomas

DNA and RNA  sequencing    Uses both DNA and RNA  sequencing for sensitive detection  of translocations and fusions    1 >400 genes,  TMB, MSI    Analyses >400  cancer-related genes and   reports TMB and MSI 1
Order

Order FoundationOne Heme

Accepted specimen types are peripheral whole blood, bone marrow aspirate, FFPE block or slides, or extracted nucleic acid. Blood and bone marrow aspirate must be received the day after collection for optimal analysis.2 Some countries may not be able to offer the FoundationOne Heme service at present. We are working to make FoundationOne Heme more broadly available.

FFPE, formalin-fixed paraffin-embedded. MSI, microsatellite instability. TMB, tumour mutational burden.
References
  1. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).
  2. FoundationOne®Heme Specimen Instructions, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).